STAT+: Warren urges FTC to probe deal that would give Novo Nordisk control of some Catalent plants
STAT
OCTOBER 10, 2024
billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.
Let's personalize your content